Lena E. Friberg

10.0k citations

215 papers · 6.8k indexed · 1 hit paper · h-index 45

Co-authors: Elisabet I. Nielsen Mats O. Karlsson Otto Cars Matti Karvanen Anja Henningsson Hugo Maas Laurent Nguyen Geoffrey K. Isbister
Topics: Antibiotics Pharmacokinetics and Efficacy (81 papers)Antibiotic Resistance in Bacteria (65 papers)Pneumonia and Respiratory Infections (25 papers)
Cited by: Molecular Medicine Applied Microbiology and Biotechnology Pharmacology
Journals: Journal of Clinical Oncology PLoS ONE American Journal of Clinical Nutrition
Partner nations: Sweden United States Netherlands

In The Last Decade

Lena E. Friberg

204 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics

2021 180 citations Elisabet I. Nielsen, Lena E. Friberg et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Lena E. Friberg

Since Specialization

Citations

This map shows the geographic impact of Lena E. Friberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lena E. Friberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lena E. Friberg more than expected).

Fields of papers citing papers by Lena E. Friberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lena E. Friberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lena E. Friberg. The network helps show where Lena E. Friberg may publish in the future.

Co-authorship network of co-authors of Lena E. Friberg

This figure shows the co-authorship network connecting the top 25 collaborators of Lena E. Friberg. A scholar is included among the top collaborators of Lena E. Friberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lena E. Friberg. Lena E. Friberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Simulation-based evaluation of the impact of dose fractionation study design on antibiotic PKPD analyses 2025 ·JAC-Antimicrobial Resistance ·(unknown),(unknown),Lena E. Friberg	0
2	Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer 2025 ·Clinical Pharmacology & Therapeutics ·Maddalena Centanni,Afroditi Nanou,Leon W.M.M. Terstappen,K. Punt,Frank Coumans,Mats O. Karlsson,Lena E. Friberg	0
3	Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children 2024 ·Cancer Chemotherapy and Pharmacology ·Maddalena Centanni,(unknown),(unknown),Mats O. Karlsson,Lena E. Friberg	1
4	Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis 2024 ·Clinical Pharmacology & Therapeutics ·(unknown),Chiara Zecchin,Aliénor Berges,Mats O. Karlsson,Lena E. Friberg	4
5	A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown),Christina Claus,R. Albrecht,(unknown),(unknown),Christine McIntyre,Tamara Tanos,(unknown),Lena E. Friberg,Siv Jönsson,Nicolas Frances	2
6	Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings 2022 ·Antibiotics ·Iris K. Minichmayr,(unknown),Margreke J. E. Brill,Lena E. Friberg	4
7	Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose 2022 ·Journal of Antimicrobial Chemotherapy ·Chenyan Zhao,(unknown),Staffan Rosenborg,(unknown),Johan Lindberg,Sven N. Hobbie,Lena E. Friberg	20
8	Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors 2022 ·Clinical and Translational Science ·Maddalena Centanni,Abel Thijs,Ingrid M.E. Desar,Mats O. Karlsson,Lena E. Friberg	3
9	A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6 2019 ·PLoS ONE ·(unknown),(unknown),Eva Tano,Markus Castegren,Miklós Lipcsey,Jan Sjölin,Mats O. Karlsson,Lena E. Friberg,Elisabet I. Nielsen	17
10	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections 2017 ·Intensive Care Medicine ·Thomas Tängdén,Véronique Martin,Tim Felton,Elisabet I. Nielsen,Sandrine Marchand,Roger J. M. Brüggemann,Jürgen B. Bulitta,Matteo Bassetti,Ursula Theuretzbacher,Brian T. Tsuji,David W. Wareham,Lena E. Friberg,Jan J. De Waele,Vincent H. Tam,Jason A. Roberts	89
11	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling 2017 ·British Journal of Clinical Pharmacology ·(unknown),Mats O. Karlsson,Elisabet I. Nielsen,Angelica Quartino,Henrik Lindman,Lena E. Friberg	11
12	Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring 2017 ·Cancer Chemotherapy and Pharmacology ·(unknown),Elisabet I. Nielsen,Lena E. Friberg,Mats O. Karlsson	16
13	CYP3A422* Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity 2013 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Laure Elens,Jason A. Sprowl,Alex Sparreboom,Lena E. Friberg,Bronno van der Holt,Pleun J. de Raaf,Peter de Bruijn,Frederike K. Engels,Ferry A.L.M. Eskens,Erik A.C. Wiemer,Jaap Verweij,Ron H.J. Mathijssen,Ron H. N. van Schaik	91
14	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel 2012 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Cynthia S. Lancaster,Amanda Obaidat,Bruno Hagenbuch,Laure Elens,Lena E. Friberg,Peter de Bruijn,Shuiying Hu,Alice A. Gibson,Gitte Hoffmann Bruun,Thomas J. Corydon,Torben Stamm Mikkelsen,Aisha L. Walker,Guoqing Du,Walter J. Loos,Ron H. N. van Schaik,Sharyn D. Baker,Ron H.J. Mathijssen,Alex Sparreboom	76
15	Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy 2012 ·Clinical Cancer Research ·Anne‐Joy M. de Graan,Walter J. Loos,Lena E. Friberg,Sharyn D. Baker,Jessica M. van der Bol,Leni van Doorn,Erik A.C. Wiemer,Bronno van der Holt,Jaap Verweij,Ron H.J. Mathijssen	29
16	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients 2012 ·Clinical Cancer Research ·Karel Eechoute,Martin N. Fransson,(unknown),Floris A. de Jong,Alex Sparreboom,Winette T.A. van der Graaf,Lena E. Friberg,Gaia Schiavon,Erik A.C. Wiemer,Jaap Verweij,Walter J. Loos,Ron H.J. Mathijssen,Ugo De Giorgi	87
17	A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan 2010 ·Clinical Cancer Research ·Jessica M. van der Bol,Ron H.J. Mathijssen,Geert-Jan Creemers,André Planting,Walter J. Loos,Erik A.C. Wiemer,Lena E. Friberg,Jaap Verweij,Alex Sparreboom,Floris A. de Jong	50
18	The Effect of Decontamination Procedures on the Pharmacokinetics of Venlafaxine in Overdose 2009 ·Clinical Pharmacology & Therapeutics ·(unknown),Sven Oscarsson,Lena E. Friberg,Geoffrey K. Isbister,L. Peter Hackett,Stephen B. Duffull	21
19	Simultaneous fit of competing models as a model discrimination tool in Bayesian analysis 2004 ·Queensland's institutional digital repository (The University of Queensland) ·Lena E. Friberg,C. Dansirikul,Stephen B. Duffull	3
20	Factors Influencing Metabolism and Toxicity of Metals: A Consensus Report 1978 ·Environmental Health Perspectives ·(unknown),Bruce A. Fowler,Lena E. Friberg,Arne Jernelöv,Natalie G. Nelson,Magnus Piscator,H H Sandstead,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	81

About Lena E. Friberg

Lena E. Friberg is a scholar working on Molecular Medicine, Pharmacology and Applied Microbiology and Biotechnology, having authored 215 papers that have together received 6.8k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (81 papers), Antibiotic Resistance in Bacteria (65 papers) and Pneumonia and Respiratory Infections (25 papers). The work is most often cited by research in Molecular Medicine (1.9k citations), Applied Microbiology and Biotechnology (371 citations) and Pharmacology (2.6k citations). Lena E. Friberg has collaborated with scholars based in Sweden, United States and Netherlands. Frequent co-authors include Elisabet I. Nielsen, Mats O. Karlsson, Otto Cars, Matti Karvanen, Anja Henningsson, Hugo Maas, Laurent Nguyen, Geoffrey K. Isbister, Stephen B. Duffull and Diamantis Plachouras. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact